Biotechnology
Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea
GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...
2022-10-18 20:35
1417
WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business
BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across differ...
2022-10-18 17:02
3931
ImmVira announced to launch the construction of Global R&D and Commercialization Base
SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay),China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on t...
2022-10-18 16:22
1790
EditForce Realizes RNA-editing Technology of "U-to-C"
FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered inFukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human ce...
2022-10-18 14:00
1751
iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis
* The transposon technology development following the customized CRISPR/Cas
system for bacteriophage
* 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South
Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",
www.intodeworld.com
2022-10-18 11:56
2013
InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022
NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology companydedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating t...
2022-10-18 08:00
1616
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia
Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...
2022-10-17 20:05
1878
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022
DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology dru...
2022-10-17 20:00
1987
Tianfu International Biocity: Build Global Bioindustry-city
CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...
2022-10-14 20:48
1811
WuXi Biologics Receives "Best CDMO Award of the Year"
SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 202...
2022-10-14 09:00
2453
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...
2022-10-13 22:25
1985
Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day
WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.Today, Neurophth Therapeutics, Inc. has a special interview with Dr.Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology ...
2022-10-13 20:30
2898
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2022-10-13 19:05
1983
Samsung Biologics obtains three global ISO certifications
* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...
2022-10-13 19:00
2026
Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®
HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...
2022-10-11 20:40
2338
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
2022-10-11 19:00
1819
Samsung Biologics unlocks additional capacity for production at its newest Plant 4
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...
2022-10-11 19:00
2052
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...
2022-10-08 10:43
2861
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
2317
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
2022-10-04 19:00
1972
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 289 media titles]
2026-04-16 15:34
Silicon Box Announces It Joins Imec Automotive Chiplet Program to Strengthen Chip Supply Chains for Next-Generation Vehicles
[Picked up by 288 media titles]
2026-04-15 21:02
Most Read
Blaize Announces Expected First Quarter 2026 Revenue and Newly Awarded Contract with NeoTensr Anticipated to Generate $50.0 Million in Revenue
2026-04-14 21:43
5914
NYSE Content Update: U.S.-Based Diversified Energy to Ring Bell for 25 Years Since its Founding
2026-04-13 21:06
5439
Makerfire Adopts Breakthrough USX51 Industrial-Grade AI Flight Controller: Empowering Enterprises to Cut Costs and Boost Efficiency in Low-Altitude Operations
2026-04-11 01:00
5359
OCI Global Publishes 2025 Annual Report and Audited Financial Statements
2026-04-11 00:49
4850